Login to Your Account

Karus' Series B Adds $7.6M for Isoform-Selective Inhibitors

By Cormac Sheridan
Staff Writer

Wednesday, September 12, 2012
Karus Therapeutics Ltd. banked $7.6 million, the first tranche of a Series B round that is intended to enable the company to take its two lead programs through human proof-of-concept studies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription